Sebastian Neumann

Roche Innovat Ctr Basel Roche Pharma Res & Early Dev

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 16 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Table S2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Marina Bacac,Tanja Fauti,Johannes Sam,Sara Colombetti,Tina Weinzierl,Djamila Ouaret,Walter Bodmer,Steffi Lehmann,Thomas Hofer,Ralf J. Hosse,Ekkehard Moessner,Oliver Ast,Peter Bruenker,Sandra Grau-Richards,Teilo Schaller, Annette Seidl,Christian Gerdes,Mario Perro,Valeria Nicolini,Nathalie Steinhoff,Sherri Dudal,Sebastian Neumann,Thomas von Hirschheydt,Christiane Jaeger,Jose Saro,Vaios Karanikas,Christian Klein,Pablo Umaña

openalex（2023）

Cited0Views0Bibtex

Supplemental Information from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

Supplemental Figure 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

Video 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

Supplemental Figure 3 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

Supplemental Figure 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

Table S1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

Video 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

openalex（2023）

Cited0Views0Bibtex

the CD25 Antibody RG6292 Selectively Depletes Tregs While Preserving IL-2 Signaling and CTL Activity for Tumor Control

Maria Amann,Gabriel Schnetzler,Kolben Theresa,Isabelle Solomon,Christophe Boetsch,Estelle Marrer-Berger, Reto Flury,Claudio Murgia,Vaios Karanikas,Johannes Sam,Roger Sutmuller,Jan Eckmann,Hans Koll,Sara Belli, Frederic Arce Vargas,Dimitrios Zervas,Chen Qing,Mark A. Brown,Josephine Salimu,Anne Goubier,Sebastian Neumann,Karl S. Peggs,Sergio A. Quezada

CANCER RESEARCH（2020）

Cited4Views0Bibtex

Cergutuzumab Amunaleukin (Cea-Il2v), A Cea- Targeted Il-2 Variant- Based Immunocytokine for Combination Cancer Immunotherapy: Overcoming Limitations of Aldesleukin and Conventional Il-2-Based Immunocytokines

Christian Klein,Inja Waldhauer,Valeria G. Nicolini,Anne Freimoser-Grundschober,Tapan Nayak,Danielle J. Vugts,Claire Dunn,Marije Bolijn, Org Benz,Martine Stihle,Sabine Lang, Michaele Roemmele,Thomas Hofer,Erwin Van Puijenbroek, David Wittig,Samuel Moser,Oliver Ast,Peter Br Unker,Ingo H. Gorr,Sebastian Neumann,Maria Cristina de Vera Mudry,Heather Hinton,Flavio Crameri,Jose Saro,Stefan Evers,Christian Gerdes,Marina Bacac,Guus Van Dongen,Ekkehard Moessner,Pablo Umana

ONCOIMMUNOLOGY（2017）

Cited236Views0WOSBibtex

236

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn